Michael is a member of the fund management team of KHAN Technology Transfer Fund (KHAN), a German early-stage life science venture fund with € 70 millions under management. At KHAN, Michael is responsible for company building and equity investments into academic spin-offs.
He is also co-founder and CEO of HeartBeat.bio AG, a Vienna-based start-up company with the mission to radically change the paradigm of cardiac drug discovery by converging unique human organoid technologies, hardware engineering, and artificial intelligence.
Michael has a degree in business administration and more than 25 years of experience as a founder, start-up manager and executive board member at several fast-growing life science organizations in Germany and Austria. Prior to that, he worked for 8 years in corporate finance and management consulting.